Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Jan 1;99(1):62–66. doi: 10.1172/JCI119134

Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes.

M C Garin 1, R W James 1, P Dussoix 1, H Blanché 1, P Passa 1, P Froguel 1, J Ruiz 1
PMCID: PMC507768  PMID: 9011577

Abstract

Paraoxonase was identified as a genetic risk factor for cardiovascular disease (CVD) in recent studies focusing on a polymorphism affecting position 191. A second polymorphism of the paraoxonase gene affects position 54 and involves a methionine (M allele) to leucine (L allele) change. It was investigated in diabetic patients (n = 408) with and without vascular disease. There were highly significant differences in plasma concentrations and activities of paraoxonase between genotypes defined by the 54 polymorphism: MMAA, MLAA, LLAA; protein, 65.3+/-18.0, 77.9+/-18.0, 93.5+/-26.0 microg/ml; P < 0.0001: activity (phenylacetate), 48.6+/-13.5, 64.1+/-14.5, 68.1+/-13.0 U/ml; P < 0.0001. The 191 variant had little impact on paraoxonase concentrations. Homozygosity for the L allele was an independent risk factor for CVD (odds ratio 1.98 (1.07-3.83); P = 0.031). A linkage disequilibrium (P < 0.0001) was apparent between the mutations giving rise to leucine and arginine at positions 54 and 191, respectively. The study underlines that susceptibility to CVD correlates with high activity paraoxonase alleles. The 54 polymorphism would appear to be of central importance to paraoxonase function by virtue of its association with modulated concentrations. The latter could explain the association between both the 54 and 191 polymorphisms and CVD.

Full Text

The Full Text of this article is available as a PDF (138.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adkins S., Gan K. N., Mody M., La Du B. N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993 Mar;52(3):598–608. [PMC free article] [PubMed] [Google Scholar]
  2. Austin M. A., Breslow J. L., Hennekens C. H., Buring J. E., Willett W. C., Krauss R. M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988 Oct 7;260(13):1917–1921. [PubMed] [Google Scholar]
  3. Blatter Garin M. C., Abbott C., Messmer S., Mackness M., Durrington P., Pometta D., James R. W. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J. 1994 Dec 1;304(Pt 2):549–554. doi: 10.1042/bj3040549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blatter M. C., James R. W., Messmer S., Barja F., Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem. 1993 Feb 1;211(3):871–879. doi: 10.1111/j.1432-1033.1993.tb17620.x. [DOI] [PubMed] [Google Scholar]
  5. Bucala R., Makita Z., Koschinsky T., Cerami A., Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6434–6438. doi: 10.1073/pnas.90.14.6434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cheung M. C., Albers J. J. Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem. 1984 Oct 10;259(19):12201–12209. [PubMed] [Google Scholar]
  7. Demant T., Carlson L. A., Holmquist L., Karpe F., Nilsson-Ehle P., Packard C. J., Shepherd J. Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J Lipid Res. 1988 Dec;29(12):1603–1611. [PubMed] [Google Scholar]
  8. Eckerson H. W., Wyte C. M., La Du B. N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983 Nov;35(6):1126–1138. [PMC free article] [PubMed] [Google Scholar]
  9. Eisenberg S. High density lipoprotein metabolism. J Lipid Res. 1984 Oct;25(10):1017–1058. [PubMed] [Google Scholar]
  10. Furlong C. E., Richter R. J., Chapline C., Crabb J. W. Purification of rabbit and human serum paraoxonase. Biochemistry. 1991 Oct 22;30(42):10133–10140. doi: 10.1021/bi00106a009. [DOI] [PubMed] [Google Scholar]
  11. Hegele R. A., Brunt J. H., Connelly P. W. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol. 1995 Jan;15(1):89–95. doi: 10.1161/01.atv.15.1.89. [DOI] [PubMed] [Google Scholar]
  12. Humbert R., Adler D. A., Disteche C. M., Hassett C., Omiecinski C. J., Furlong C. E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993 Jan;3(1):73–76. doi: 10.1038/ng0193-73. [DOI] [PubMed] [Google Scholar]
  13. Hunt J. V., Smith C. C., Wolff S. P. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes. 1990 Nov;39(11):1420–1424. doi: 10.2337/diab.39.11.1420. [DOI] [PubMed] [Google Scholar]
  14. Kelso G. J., Stuart W. D., Richter R. J., Furlong C. E., Jordan-Starck T. C., Harmony J. A. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 1994 Jan 25;33(3):832–839. doi: 10.1021/bi00169a026. [DOI] [PubMed] [Google Scholar]
  15. Krolewski A. S., Warram J. H., Valsania P., Martin B. C., Laffel L. M., Christlieb A. R. Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med. 1991 Feb 21;90(2A):56S–61S. doi: 10.1016/0002-9343(91)90040-5. [DOI] [PubMed] [Google Scholar]
  16. Mackness M. I., Arrol S., Abbott C., Durrington P. N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993 Dec;104(1-2):129–135. doi: 10.1016/0021-9150(93)90183-u. [DOI] [PubMed] [Google Scholar]
  17. Mackness M. I., Arrol S., Durrington P. N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991 Jul 29;286(1-2):152–154. doi: 10.1016/0014-5793(91)80962-3. [DOI] [PubMed] [Google Scholar]
  18. Mackness M. I., Durrington P. N. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 1995 Jun;115(2):243–253. doi: 10.1016/0021-9150(94)05524-m. [DOI] [PubMed] [Google Scholar]
  19. Mackness M. I., Durrington P. N. Paraoxonase: another factor in NIDDM cardiovascular disease. Lancet. 1995 Sep 30;346(8979):856–856. doi: 10.1016/s0140-6736(95)92702-6. [DOI] [PubMed] [Google Scholar]
  20. Mackness M. I., Peuchant E., Dumon M. F., Walker C. H., Clerc M. Absence of "A"-esterase activity in the serum of a patient with Tangier disease. Clin Biochem. 1989 Dec;22(6):475–478. doi: 10.1016/s0009-9120(89)80101-8. [DOI] [PubMed] [Google Scholar]
  21. Mackness M. I., Walker C. H., Carlson L. A. Low A-esterase activity in serum of patients with fish-eye disease. Clin Chem. 1987 Apr;33(4):587–588. [PubMed] [Google Scholar]
  22. Patsch J. R., Prasad S., Gotto A. M., Jr, Patsch W. High density lipoprotein2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest. 1987 Aug;80(2):341–347. doi: 10.1172/JCI113078. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pyörälä K., Laakso M., Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987 Apr;3(2):463–524. doi: 10.1002/dmr.5610030206. [DOI] [PubMed] [Google Scholar]
  24. Ruiz J., Blanché H., James R. W., Garin M. C., Vaisse C., Charpentier G., Cohen N., Morabia A., Passa P., Froguel P. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 1995 Sep 30;346(8979):869–872. doi: 10.1016/s0140-6736(95)92709-3. [DOI] [PubMed] [Google Scholar]
  25. Saha N., Roy A. C., Teo S. H., Tay J. S., Ratnam S. S. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet. 1991 Oct;40(4):277–282. doi: 10.1111/j.1399-0004.1991.tb03096.x. [DOI] [PubMed] [Google Scholar]
  26. Serrato M., Marian A. J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. 1995 Dec;96(6):3005–3008. doi: 10.1172/JCI118373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sorenson R. C., Primo-Parmo S. L., Kuo C. L., Adkins S., Lockridge O., La Du B. N. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7187–7191. doi: 10.1073/pnas.92.16.7187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Tribble D. L. Lipoprotein oxidation in dyslipidemia: insights into general mechanisms affecting lipoprotein oxidative behavior. Curr Opin Lipidol. 1995 Aug;6(4):196–208. [PubMed] [Google Scholar]
  29. Watson A. D., Berliner J. A., Hama S. Y., La Du B. N., Faull K. F., Fogelman A. M., Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995 Dec;96(6):2882–2891. doi: 10.1172/JCI118359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Witztum J. L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991 Dec;88(6):1785–1792. doi: 10.1172/JCI115499. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES